|
|
Profile
|
Delegates :
Takumi Kawabe |
|
Incorporated :
January 18 , 2000 |
Paid in Capital :
3400 Million yen |
Employees :
13 人 |
Address :
2-2-1 Otemachi, Numazu SHIZUOKA
〒4100801
|
TEL/FAX :
+81-55-954-3666 / +81-954-3668 |
URL：
http://www.canbas.co.jp |
Attachment :
 CBP501_non-confd.zip [ 1.5MiB ] |
Mission/Background :
CanBas was named after "cancer busters" to conquer cancer by a small group and "canvas" that is an image for the freedom of each and every person. Our mission is to conquer cancer. We are trying to find cure(s) for cancer patients based on our long experience in the bed side and laboratory. We established an excellent scientific advisory board in which Prof. Kufe at Dana Farber Cancer Institute, Prof. Von Hoff at Ariszona Cancer Center and TGen, and Prof. Dunphy at California Institute of Technology are in. Based on their excellent advice we are doing basic research, drug screening, chemical optimization, preclinical studies and clinical studies under US FDA IND. |
|
Technology & Business
|
We have established a proprietary drug screening system which differenciate normal versus cancerous cells based on the cell cycle G2 checkpoint related phenotype. We obtained two major pipe lines by this method, CBP501 and CBS9106. CBP501 is a unique calmodulin modulator which increases platinum uptake of tumor cells specifically. It also suppresses tumor associated macrophases which leads to the suppression of metastasis, reduction of cancer stem cells, and augmention of tumor immunogenicity. CBS9106 is a XPO1/CRM1 inhibitor which leads to the accumulation of tumor suppressors in the nucleus in tumor cells and kill them.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
CBP501
|
Phase1/2
|
Started a Phase Ib for triple drug combination, CBP501+CDDP+anti-PD1, in US
|
Find a partner
|
CBS9106
|
Phase1
|
Licensed out world wide right, except Japan, China, Korea and Taiwan, to Stemline Therapeutics.
|
Finding a partner for the Asian rights including Japan.
|
CBP-A08
|
Preclinical
|
Next generation peptide anti-cancer drug candidate
|
Find a partner to develop it.
|
IDO/TDO dual inhibitor
|
Discovery
|
Close to identify best compound.
|
Find a partner to develop it.
|
|
|
|
|
|
Highlights
|
WBC/CBP501 patent filed
3 poster presentations on additional function of CBP501 at AACR-NCI-EORTC meeting 2015 in Boston
2 papers published in Oncotarget on EMT suppression and macrophage suppression by CBP501.
|
|
Hot news
|
We have established and preclinically proved a molecular mechanism of action of CBP501 that led to the prolongation of overall survival in nin-small cell lung cancer patients in the global Phase II study.
|
|
Alliance strategy
|
Looking for partners for CBP501, CBP-A08, or IDO/TDO dual inhibitor.
|
|
|